Document:

EX-10.13

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.13 
 Amendment to
Anemia License and Collaboration Agreement 
 This Amendment (the “Amendment”) to the Anemia License and Collaboration Agreement
dated as of April 28, 2006, by and between Astellas Pharma Inc. and FibroGen, Inc. (the “Agreement”) shall be effective as of August 31, 2006. 

The Parties, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, agree as follows: 

 

	 	(1)	Item i) of the Section of the Agreement entitled “Upfront and Milestone Payments to FibroGen” (hereinafter the “Upfront Section”) shall be amended in its entirety to read as follows: “$40
million US dollars within fourteen (14) business days in Japan of execution of this Agreement, $20 million US dollars within fourteen (14) business day in Japan of issuance by FibroGen to Astellas of an invoice after the execution of this
Amendment, $20 million US dollars within fourteen (14) business days in Japan of the earlier of the execution of the Detailed Commercialization Agreement (as defined below) or the conversion of the Agreement into the final operative Agreement,
$70 million US dollars on January 31, 2007, $70 million dollars on January 31,2008, and $80 million US dollars on January 31,2009 (collectively, the “Upfront Payments”);” 

 

	 	(2)	Item ii) of the Upfront Section shall be amended in its entirety to read as follows: “$20 million US dollars upon submission by FibroGen to Astellas of written notice that the first Phase IIb clinical trial
(provided such trial is included within Exhibit D attached hereto) has been Initiated for a first Product in any of the Core Indications (except for [ * ]) in any country in the EU or the US;” 

 

	 	(3)	A new Item iii) of the Upfront Section shall be added as follows: “$20 million US dollars upon Initiation after the execution of this Amendment of the next Phase IIb clinical trial (provided such trial is included
within the Transatlantic Clinical Development Plan, contained in Exhibit D attached hereto, or is otherwise agreed by the Parties, and such trial is for a different Core Indication than the Core Indication studied under the Phase IIb clinical trail
in item ii) above) for the same Product that triggered the milestone payment under ii) above in any of the Core Indications (except for [ * ]) in any country in the EU or the US;” 

 

	 	(4)	The current Items iii) through vi) of the Upfront Section shall be renumbered as Items iv) through vii), respectively, and the paragraph immediately below new Item vii) shall be amended in its entirety to read as
follows: “Each of the payments to be made under (ii)–(vii) above and under the “Milestone Payments to FibroGen for Approval Success” section below shall be a “Milestone Payment” for the purposes of this
Agreement.” 

  

					
	Confidential	 		 	

	 	(5)	The Section of the Agreement entitled “Legal Effect” shall be amended in its entirety to read as follows: “This Agreement shall constitute the operative agreement between FibroGen and Astellas and shall
be in full force and effect as of its execution by the parties. The parties shall make best efforts to enter into a more detailed collaboration agreement reflecting more fully the terms and conditions of this Agreement (the “Detailed
Commercialization Agreement”) by December 1, 2006. If the parties do not enter into a Detailed Commercialization Agreement by such date, then this Agreement shall become the final operative agreement governing the relationship between the
parties.” 

  

	 	(6)	Except as otherwise provided herein, the Agreement has not been modified or amended and remains in full force and effect. 

IN WITNESS WHEREOF, the Parties have executed this Amendment to Anemia License and Collaboration Agreement as of the date first set forth
above. 
  

			
	FIBROGEN, INC.
		
	By:  	 	 /s/ William Hodder

		 	William Hodder
		 	Vice President, Business Development

 
			
	  
 ASTELLAS PHARMA INC.

		
	By:  	 	 /s/ Masaki Doi

		 	Masaki Doi
		 	Vice President, Business Development

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.14

 Exhibit 10.14 

Amendment No. 2 to Anemia License and Collaboration Agreement 

This Amendment No 2. (the “Amendment”) to the Anemia License and Collaboration Agreement dated as of April 28, 2006, as amended
on August 31, 2006, by and between Astellas Pharma Inc. and FibroGen, Inc. (the “Agreement”) shall be effective as of December 1, 2006. 

The Parties, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, agree as follows: 

 

	 	(1)	Item i) of the Section of the Agreement entitled “Upfront and Milestone Payments to FibroGen” (hereinafter the “Upfront Section”) shall be amended in its entirety to read as follows: “$40
million US dollars within fourteen (14) business days in Japan of execution of this Agreement, $20 million US dollars on September 15, 2006, $20 million US dollars on or prior to December 28, 2006, $50 million US dollars on
January 31, 2007, $20 million US dollars within fourteen (14) business days in Japan of the earlier of the execution of the Detailed Commercialization Agreement (as defined below) or the conversion of the Agreement into the final operative
Agreement, $70 million US dollars on January 31, 2008, and $80 million US dollars on January 31, 2009 (collectively, the “Upfront Payments”);” 

 

	 	(2)	The Section of the Agreement entitled “Legal Effect” shall be amended in its entirety to read as follows: “This Agreement shall constitute the operative agreement between FibroGen and Astellas and shall
be in full force and effect as of its execution by the parties. The parties shall make best efforts to enter into a more detailed collaboration agreement reflecting more fully the terms and conditions of this Agreement (the “Detailed
Commercialization Agreement”) by March 31, 2007. If the parties do not enter into a Detailed Commercialization Agreement by such date, then this Agreement shall become the final operative agreement governing the relationship between the
parties.” 

  

	 	(3)	Except as otherwise provided herein, the Agreement has not been modified or amended and remains in full force and effect. 

  
 Confidential 

 IN WITNESS WHEREOF, the Parties have executed this Amendment to Anemia License and Collaboration
Agreement as of the date first set forth above. 
  

			
	FIBROGEN, INC.
		
	By:	 	 /s/ William Hodder

		 	William Hodder
		 	Vice President, Business Development

  

			
	ASTELLAS PHARMA INC.
		
	By:	 	 /s/ Masaki Doi

		 	Masaki Doi, Ph.D.
		 	Vice President, Business Development

  
 ConfidentialEX-10.15

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.15 
 Supplement to
Anemia License and Collaboration Agreement 
 This Supplement (this “Supplement”) to the Anemia License and Collaboration
Agreement dated as of April 28, 2006, as amended, by and between Astellas Pharma Inc. and FibroGen, Inc. (the “Agreement”) is dated as of November 12, 2009, and shall be effective as of April 28, 2006. Astellas and FibroGen
are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.” All capitalized terms not otherwise defined in this Supplement have the same meanings as set forth in the Agreement. 

Whereas, the Development Costs section of the Agreement provides that reasonable FTE costs shall be included in the costs shared under the
Agreement, and the Parties have been in discussions to clarify the cost structure governing development activities for which costs are shared under the Agreement; 

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree, for the
purposes of clarification, as follows: 
  

	 	(1)	The Parties agree that the rate for reasonable FTE costs for which each Party will charge the other for eligible activities performed by employees of such Party and its Affiliates and for which costs are shared under
the Agreement shall be calculated on an hourly basis for the hours actually worked (the “Hourly Rate”). The Hourly Rate shall be, for the period commencing on the Effective Date of the Agreement and ending December 31, 2007,
$[ * ] per hour; for the period from January 1, 2008 to December 31,2008, the FTE Rate shall be $[ * ] per hour; for the period from January 1, 2009 to December 31, 2009, the FTE Rate shall be $[ * ]
per hour; and thereafter, the FTE Rate shall be adjusted annually as of January 1, beginning on January 1, 2010, in accordance with the average annual percentage [ * ] for the preceding year, calculated from the [ * ]
of [ * ] and [ * ] for the [ * ] for such annual period, except as otherwise mutually agreed by the Parties. For the purposes of clarity, the [ * ] shall be [ * ], and the [ * ] for the
[ * ] shall be [ * ]; and the current [ * ] for these [ * ] are located on Exhibit A hereto, as may be amended from time to time. The intent of the Hourly Rate is to represent a fully loaded rate that
includes, but is not limited to, the following general expense categories: salaries and wages (including bonuses, moving expenses, and payroll taxes), benefits provided (including health benefits, defined contribution, defined benefit plans,
vacations, etc.), direct employee costs (including recruitment costs, internal and external training costs, computer charges, automobile leases, subscriptions and reference materials, telephone, fax, cellular phone, and copy machines and related
costs), and allocation of other overhead costs (including rent, insurance, and utilities). 

 Confidential 

	 	(2)	Except as otherwise provided herein, the Agreement has not been modified or amended and remains in full force and effect. 

IN WITNESS WHEREOF, the Parties have executed this Supplement to Anemia License and Collaboration Agreement as of the date first set forth
above. 
  

			
	FIBROGEN, INC.
		
	By:  	 	     /s/ William Hodder

		 	William Hodder
		 	Vice President, Business Development

 
			
	  
 ASTELLAS PHARMA INC.

		
	By:  	 	     /s/ C. Yokota

		 	Chihiro Yokota, R.Ph.
		 	Vice President, Licensing & Alliances

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A 

[ * ] 
 [ * ] 

 
 [ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]